Clascoterone: a new topical antiandrogen agent.
DOI:
https://doi.org/10.56782/pps.258Keywords:
clascoterone, klaskoteron, androgen inhibitor, topical acne therapy, androgenetic alopeciaAbstract
Androgen hormones (androgens) and androgen receptors (ARs) play both a significant role in the pathogenesis of certain skin disorders, such as acne vulgaris (hereafter: acne) and androgenetic alopecia (AGA) in both males and females. Systemic antiandrogen therapies, such as oral contraceptives (DTAs) and spironolactone, are potentially effective strategies for the treatment of acne and AGA. However, they are associated with systemic adverse effects and are unsuitable for use in males. Clascoterone cream, 1%, is a novel topical androgen receptor inhibitor (ARI). The use of a topical antiandrogen drug significantly reduces the risk of these side effects. Clascotereone is currently the only topical ARI approved by the Food and Drug Administration (FDA). It is indicated for patients 12 years of age and older with facial acne vulgaris. Several clinical studies demonstrated the effectiveness of clascoterone in treating acne with a favorable safety profile. The other indications for clascoterone, including the treatment of AGA, are currently under investigation. The promising results from clinical trials suggest that clascoterone may soon play a broader role in dermatology, offering benefits for conditions that currently have limited treatment options.
Downloads
References
1. Chen, W.; Zouboulis, C. C.; et al. Evidence of heterogeneity and quantitative differences of the type 1 5alpha-reductase expression in cultured human skin cells – evidence of its presence in melanocytes. J. Invest. Dermatol. 1998, 110 (1), 84-89. DOI: 10.1046/j.1523-1747.1998.00080.x DOI: https://doi.org/10.1046/j.1523-1747.1998.00080.x
2. Lai, J. J.; Chang, P.; et al. The role of androgen and androgen receptor in skin-related disorders. Arch. Dermatol. Res. 2012, 304 (7), 499-510. DOI: 10.1007/s00403-012-1265-x DOI: https://doi.org/10.1007/s00403-012-1265-x
3. Zouboulis, C. C.; Chen, W. C.; et al. Sexual hormones in human skin. Horm. Metab. Res. 2007, 39 (2), 85-95. DOI: 10.1055/s-2007-961807 DOI: https://doi.org/10.1055/s-2007-961807
4. Nestor, M. S.; Ablon, G.; et al. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J. Cosmet. Dermatol. 2021, 20 (12), 3759-3781. DOI: 10.1111/jocd.14537 DOI: https://doi.org/10.1111/jocd.14537
5. Kircik, L. H. Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist. Expert Opin. Pharmacother. 2021, 22 (13), 1801-1806. DOI: 10.1080/14656566.2021.1918100 DOI: https://doi.org/10.1080/14656566.2021.1918100
6. Rosette, C.; Rosette, N.; et al. Cortexolone 17alpha-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro. J. Drugs Dermatol. 2019, 18 (2), 197-201.
7. Ferraboschi, P.; Chiara Sala, M.; et al. Full spectroscopic characterization of two crystal pseudopolymorphic forms of the antiandrogen cortexolone 17alpha-propionate for topic application. Steroids 2017, 128, 95-104. DOI: 10.1016/j.steroids.2017.09.003 DOI: https://doi.org/10.1016/j.steroids.2017.09.003
8. Mazzetti, A.; Moro, L.; et al. Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study. J. Drugs Dermatol. 2019, 18 (6), 563-568.
9. Bhatia, N.; Eichenfield, L. F.; et al. Hypothalamic-Pituitary-Adrenal Axis Response in Patients With Acne Vulgaris Treated With Clascoterone. J. Drugs Dermatol. 2024, 23 (6), 433-437. DOI: 10.36849/JDD.7997 DOI: https://doi.org/10.36849/JDD.7997
10. Hebert, A.; Thiboutot, D.; et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020, 156 (6), 621-630. DOI: 10.1001/jamadermatol.2020.0465 DOI: https://doi.org/10.1001/jamadermatol.2020.0465
11. Del Rosso, J.; Stein Gold, L.; et al. Is There a Clinically Relevant Risk of Hyperkalemia with Topical Clascoterone Treatment? J. Clin. Aesthet. Dermatol. 2023, 16 (6), 20-24.
12. Eichenfield, L. F.; Hebert, A. A.; et al. Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris. J. Drugs Dermatol. 2023, 22 (8), 810-816. DOI: 10.36849/jdd.7592 DOI: https://doi.org/10.36849/jdd.7592
13. Heng, A. H. S.; Chew, F. T. Systematic review of the epidemiology of acne vulgaris. Sci. Rep. 2020, 10 (1), Art. No: 5754. DOI: 10.1038/s41598-020-62715-3 DOI: https://doi.org/10.1038/s41598-020-62715-3
14. Williams, H. C.; Dellavalle, R. P.; et al. Acne vulgaris. Lancet 2012, 379 (9813), 361-372. DOI: 10.1016/S0140-6736(11)60321-8 DOI: https://doi.org/10.1016/S0140-6736(11)60321-8
15. Zaenglein, A. L.; Pathy, A. L.; et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 2016, 74 (5), 945-973.e33. DOI: 10.1016/j.jaad.2015.12.037 DOI: https://doi.org/10.1016/j.jaad.2015.12.037
16. Ghosh, S.; Chaudhuri, S.; et al. Profiling and hormonal therapy for acne in women. Indian J. Dermatol. 2014, 59 (2), 107-115. DOI: 10.4103/0019-5154.127667 DOI: https://doi.org/10.4103/0019-5154.127667
17. Chalker, D. K.; Lesher, J. L., Jr.; et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J. Am. Acad. Dermatol. 1987, 17 (2 Pt 1), 251-254. DOI: 10.1016/s0190-9622(87)70200-x DOI: https://doi.org/10.1016/S0190-9622(87)70200-X
18. Thiboutot, D.; Pariser, D. M.; et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J. Am. Acad. Dermatol. 2006, 54 (2), 242-250. DOI: 10.1016/j.jaad.2004.10.879 DOI: https://doi.org/10.1016/j.jaad.2004.10.879
19. Gollnick, H. P.; Draelos, Z.; et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br. J. Dermatol. 2009, 161 (5), 1180-1189. DOI: 10.1111/j.1365-2133.2009.09209.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09209.x
20. Chalker, D. K.; Shalita, A.; et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J. Am. Acad. Dermatol. 1983, 9 (6), 933-936. DOI: 10.1016/s0190-9622(83)70211-2 DOI: https://doi.org/10.1016/S0190-9622(83)70211-2
21. Lookingbill, D. P.; Chalker, D. K.; et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J. Am. Acad. Dermatol. 1997, 37 (4), 590-595. DOI: 10.1016/s0190-9622(97)70177-4 DOI: https://doi.org/10.1016/S0190-9622(97)70177-4
22. Babaeinejad, S.; Khodaeiani, E.; et al. Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: What is the role of age? J. Dermatolog. Treat. 2011, 22 (4), 206-210. DOI: 10.3109/09546631003762639 DOI: https://doi.org/10.3109/09546631003762639
23. Bossuyt, L.; Bosschaert, J.; et al. Lymecycline in the treatment of acne: an efficacious, safe and cost-effective alternative to minocycline. Eur. J. Dermatol. 2003, 13 (2), 130-135.
24. Villani, A.; Nastro, F.; et al. Oral isotretinoin for acne: a complete overview. Expert Opin. Drug Saf. 2022, 21 (8), 1027-1037. DOI: 10.1080/14740338.2022.2102605 DOI: https://doi.org/10.1080/14740338.2022.2102605
25. Trivedi, M. K.; Shinkai, K.; et al. A Review of hormone-based therapies to treat adult acne vulgaris in women. Int. J. Womens Dermatol. 2017, 3 (1), 44-52. DOI: 10.1016/j.ijwd.2017.02.018 DOI: https://doi.org/10.1016/j.ijwd.2017.02.018
26. Trifu, V.; Tiplica, G. S.; et al. Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br. J. Dermatol. 2011, 165 (1), 177-183. DOI: 10.1111/j.1365-2133.2011.10332.x DOI: https://doi.org/10.1111/j.1365-2133.2011.10332.x
27. Mazzetti, A.; Moro, L.; et al. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne. J. Drugs Dermatol. 2019, 18 (6), 570-575.
28. Piszczatoski, C. R.; Powell, J. Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years. Clin. Ther. 2021, 43 (10), 1638-1644. DOI: 10.1016/j.clinthera.2021.08.007 DOI: https://doi.org/10.1016/j.clinthera.2021.08.007
29. Reynolds, R. V.; Yeung, H.; et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 2024, 90 (5), 1006.e1001-1006.e1030. DOI: 10.1016/j.jaad.2023.12.017 DOI: https://doi.org/10.1016/j.jaad.2023.12.017
30. Riis, P. T.; Ring, H. C.; et al. The Role of Androgens and Estrogens in Hidradenitis Suppurativa - A Systematic Review. Acta Dermatovenerol. Croat. 2016, 24 (4), 239-249.
31. Der Sarkissian, S. A.; Sun, H. Y.; et al. Cortexolone 17alpha-propionate for hidradenitis suppurativa. Dermatol. Ther. 2020, 33 (6), Art. No: e14142. DOI: 10.1111/dth.14142 DOI: https://doi.org/10.1111/dth.14142
32. Cunningham, K. N.; Moody, K.; et al. Use of topical clascoterone for the treatment of hidradenitis suppurativa. JAAD Case Rep. 2023, 36, 38-39. DOI: 10.1016/j.jdcr.2023.04.002 DOI: https://doi.org/10.1016/j.jdcr.2023.04.002
33. Adil, A.; Godwin, M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2017, 77 (1), 136-141.e135. DOI: 10.1016/j.jaad.2017.02.054 DOI: https://doi.org/10.1016/j.jaad.2017.02.054
34. Lolli, F.; Pallotti, F.; et al. Androgenetic alopecia: a review. Endocrine 2017, 57 (1), 9-17. DOI: 10.1007/s12020-017-1280-y DOI: https://doi.org/10.1007/s12020-017-1280-y
35. Kanti, V.; Messenger, A.; et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J. Eur. Acad. Dermatol. Venereol. 2018, 32 (1), 11-22. DOI: 10.1111/jdv.14624 DOI: https://doi.org/10.1111/jdv.14624
36. Dhillon, S. Clascoterone: First Approval. Drugs 2020, 80 (16), 1745-1750. DOI: 10.1007/s40265-020-01417-6 DOI: https://doi.org/10.1007/s40265-020-01417-6
37. Sun, H. Y.; Sebaratnam, D. F. Clascoterone as a novel treatment for androgenetic alopecia. Clin. Exp. Dermatol. 2020, 45 (7), 913-914. DOI: 10.1111/ced.14292 DOI: https://doi.org/10.1111/ced.14292
38. FDA-approved Winlevi® is the first novel topical mechanism for acne in nearly 40 years. . https://www.cosmopharma.com/products/winlevi (accessed 10 Dec 2024).
39. How much is Winlevi without insurance? . https://www.singlecare.com/blog/winlevi-without-insurance/ (accessed 10 Dec2024).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Piotr Armański, Katarzyna Herjan
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
